|Bid||6.65 x 800|
|Ask||8.03 x 1000|
|Day's Range||6.66 - 7.10|
|52 Week Range||6.20 - 13.98|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.50|
Subscribe to Yahoo Finance Plus to view Fair Value for PSTXLearn more
The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Poseida Therapeutics The
Eric Ostertag, Insider at Poseida Therapeutics (NASDAQ:PSTX), made a large insider sell on November 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Ostertag sold 18,924 shares of Poseida Therapeutics at a price of $7.09. The total transaction amounted to $134,171. Ostertag still owns a total of 3,519,151 shares of Poseida Therapeutics worth, $24,959,930. Poseida Therapeutics shares are trading up 1.03% at $7.